yingweiwo

Dasatinib (BMS354825; Sprycel)

Alias: Trade name: Sprycel; BMS-354825; BMS354825; Sprycel; BMS-354825; Dasatinib anhydrous; BMS 354825; Dasatinib (anhydrous); BMS354825. Dasatinib;
Cat No.:V0629 Purity: =99.81%
Dasatinib (formerly known as BMS-354825; sold under the brand name Sprycel), is a novel, potent and multi-targeted, orally bioavailable synthetic small molecule inhibitor that targets Abl, Src and c-Kitwith potential antitumor activity.
Dasatinib (BMS354825; Sprycel)
Dasatinib (BMS354825; Sprycel) Chemical Structure CAS No.: 302962-49-8
Product category: Bcr-Abl
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
100mg
500mg
1g
5g
10g
Other Sizes

Other Forms of Dasatinib (BMS354825; Sprycel):

  • Dasatinib HCl
  • Dasatinib Monohydrate (BMS354825; Sprycel)
  • N-Deshydroxyethyl Dasatinib-d8
  • Dasatinib D8
  • Dasatinib carbaldehyde
  • Dasatinib N-oxide
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: =99.81%

Product Description

Dasatinib (formerly known as BMS-354825; sold under the brand name Sprycel), is a novel, potent and multi-targeted, orally bioavailable synthetic small molecule inhibitor that targets Abl, Src and c-Kit with potential antitumor activity. It inhibits Abl, Src and c-Kit with IC50s of<1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib is a chemotherapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+)Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.

Biological Activity I Assay Protocols (From Reference)
Targets
Bcr-Abl (IC50 = 1.0 nM); Src (IC50 = 0.5 nM); lck (IC50 = 0.4 nM); yes (IC50 = 0.5 nM); c-kit (IC50 = 5.0 nM); PDGFRβ (IC50 = 28 nM); p38 (IC50 = 100 nM); Her1 (IC50 = 180 nM); Her2 (IC50 = 710 nM); FGFR-1 (IC50 = 880 nM); MEK (IC50 = 1700 nM)
ln Vitro
Against Bcr-Abl, Src, Lck, Yes, c-Kit, PDGFRβ, p38, Her1, Her2, FGFR-1, and MEK, dasatinib exhibits noteworthy action, with IC50 values of less than 1.0, 0.50, 0.40, 0.50, 5.0, 28, 100, 180, 720, 880, and 1700 nM, respectively[1]. With an IC50 of less than 1.0 nM and 9.4 nM, respectively, dasatinib demonstrated antiproliferative action when compared to the K562 chronic myelogenous leukemia (CML), PC3 human prostate tumor, MDA-MB-231 human breast tumor, and WiDr human colon carcinoma cell line. 52 nM and 12 nM[1].
ln Vivo
Dasatinib (10 mg/kg) has a pharmacokinetic profile that is appropriate for further in vivo efficacy research. Dasatinib (5 mg/kg and 50 mg/kg, qd) has modest toxicity at different dose levels and is resolved [1]. When administered intravenously or orally, dasatinib (10 mg/kg) has a good half-life (t1/2s) of 3.3 and 3.1 hours, respectively. In this study, the oral bioavailability (Fpo) was 27% [1].
Enzyme Assay
Kinase autophosphorylation assays with glutathione S-transferase–Abl kinase domains. [2]
Kinase assays using wild-type and mutant glutathione S-transferase (GST)–Abl fusion proteins (c-Abl amino acids 220-498) were done as described, with minor alterations (15). GST-Abl fusion proteins were released from glutathione-Sepharose beads before use; the concentration of ATP was 5 μmol/L. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins were treated with LAR tyrosine phosphatase according to the manufacturer's instructions. After 1-hour incubation at 30°C, LAR phosphatase was inactivated by addition of sodium vanadate (1 mmol/L). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase was routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The inhibitor concentration ranges for IC50 determinations were 0 to 5,000 nmol/L (imatinib and AMN107) or 0 to 32 nmol/L (Dasatinib (BMS354825) ). The BMS-354825 concentration range was extended to 1,000 nmol/L for mutant T315I. These same inhibitor concentrations were used for the in vitro peptide substrate phosphorylation assays. The three inhibitors were tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
In vitro peptide substrate phosphorylation assays with glutathione S-transferase–Abl kinase domains. [2]
he effects of imatinib (0-5,000 nmol/L), AMN107 (0-5,000 nmol/L), and Dasatinib (BMS354825) (0-32 nmol/L) on the catalytic activity of unphosphorylated GST-Abl kinase were assessed using a synthetic, NH2-terminal biotin-linked peptide substrate (biotin-EAIYAAPFAKKK-amide; ref. 16). Assays were carried out at 30°C for 5 minutes in 25 μL of reaction mixture consisting of kinase buffer [25 mmol/L Tris-HCl (pH 7.5), 5 mmol/L β-glycerophosphate, 2 mmol/L DTT, 0.1 mmol/L Na3VO4, 10 mmol/L MgCl2], 50 μmol/L peptide substrate, 10 nmol/L wild-type or mutant GST-Abl kinase, and 50 μmol/L ATP/[γ-32P]ATP (5,000 cpm/pmol). Reactions were terminated by addition of guanidine hydrochloride to a final concentration of 2.5 mol/L. A portion of each terminated reaction mixture was transferred to a streptavidin-coated membrane, washed, and dried according to the manufacturer's instructions; phosphate incorporation was determined by scintillation counting. Results were corrected for background binding to the membranes as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity preceded kinase assays. Similar in vitro peptide substrate phosphorylation assays were conducted with two Src family kinases: GST-Src kinase and GST-Lyn kinase. For Src family kinases, SignaTECT PTK biotinylated peptide substrate 2 was the peptide substrate; all other conditions were as described for the GST-Abl kinase assays.
Cell Assay
Mastocytosis is associated with an activating mutation in the KIT oncoprotein (KITD816V) that results in autophosphorylation of the KIT receptor in a ligand-independent manner. This mutation is inherently resistant to imatinib and, to date, there remains no effective curative therapy for systemic mastocytosis associated with KITD816V. Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML). Pharmacokinetic analysis suggests that high nanomolar concentrations of dasatinib can be achieved safely in humans. In this study, we demonstrate significant inhibitory activity of dasatinib against both wild-type KIT and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays. Additionally, dasatinib leads to growth inhibition of a KITD816V-harboring human masto-cytosis cell line. Significantly, dasatinib selectively kills primary neoplastic bone marrow mast cells from patients with systemic mastocytosis while sparing other hematopoietic cells. Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of KIT by dasatinib. Based upon our results, further evaluation of dasatinib for the treatment of systemic masto-cytosis in clinical trials is warranted. Moreover, dasatinib may be of clinical utility in other disease settings driven by activating KIT mutations.[3]
Animal Protocol
Animal/Disease Models: Nude mice bearing K562 xenografts
Doses: 5 mg/kg and 50 mg/kg
Route of Administration: Oral administration on a 5 day on and 2 day off schedule.
Experimental Results: demonstrated partial tumor regressions after one treatment cycle and complete disappearance of the tumor mass by the end of drug treatment. No toxicity (animal deaths, lack of weight gain) was observed.

Animal/Disease Models: SD (Sprague-Dawley) Rats
Doses: 10 mg/kg (pharmacokinetic/PK Analysis)
Route of Administration: Oral and iv
Experimental Results: Cmax of 13.2 and 0.5 μM for iv and po (oral gavage) respectively.
Mouse 4 hour oral exposure assay [1]
The in vivo exposure of compounds were assessed in male Balb-c mice after administration of a single oral dose of 50 mg/kg. The vehicle used was propylene glycol:water (1:1). There were three mice per compound. The mice were fasted overnight and throughout the study. Serum concentrations in mice were collected at 30 min, 1 and 4 h after oral dosing. Samples were analyzed for each compound by LC/MS/MS. Composite serum concentration-time profiles were constructed for pharmacokinetic analysis.
Rat pharmacokinetic study [1]
The pharmacokinetics of BMS-354825 were investigated in male Sprague-Dawley rats which were fasted overnight, following a single dose of 10 mg/kg either intravenously (IV) as a 10 minute infusion or orally by gavage. There were three rats per group The dosing vehicle used was propylene glycol:water (1:1). The rats were fed 4 h post dose. Blood samples were collected at 15, 30, 45 min, 1, 2, 4, 6, 8 and 10 h after IV and oral dosing. An additional 10 min sample was collected after IV dosing. Approximately 0.3 ml of blood was collected from the jugular vein in tubes containing EDTA, and plasma was obtained by centrifugation. Plasma samples were stored at -20ºC until analysis. Samples were analyzed for BMS-354825 by LC/MS/MS.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Dasatinib has a dose-proportional pharmacokinetic profile and a linear elimination between 15 mg/day (0.15 times the lowest approved recommended dose) and 240 mg/day (1.7 times the highest approved recommended dose). At 100 mg once a day, dasatinib has a Cmax and AUC of 82.2 ng/mL and 397 ng/mL*hr, respectively. In healthy adult subjects given dasatinib as dispersed tablets in juice, the adjusted geometric mean ratio compared to intact tablets was 0.97 for Cmax, and 0.84 for AUC. The Tmax of dasatinib is between 0.5 and 6 hours following oral administration. Following a single dose of 100 mg, a high-fat meal increases the AUC of dasatinib by 14%.
Dasatinib is mainly eliminated via feces. Within 10 days, 4% of dasatinib is recovered in urine, while 85% is recovered in feces. Approximately 0.1% and 19% of the administered dasatinib dose was recovered unchanged in urine and feces, respectively, and the rest was recovered as metabolites.
Dasatinib has an apparent volume of distribution of 2505 L.
The clearance of dasatinib does not vary over time. Dasatinib has an apparent oral clearance of 363.8 L/hr.
Metabolism / Metabolites
In humans, dasatinib is mainly metabolized by CYP3A4, although flavin-containing monooxygenase 3 (FMO3) and uridine diphosphate-glucuronosyltransferase (UGT) enzymes are also involved in the formation of dasatinib metabolites. Five pharmacologically active dasatinib metabolites have been identified: M4, M5, M6, M20 and M24. M4, M20, and M24 are mainly generated by CYP3A4, M5 is generated by FMO3, and M6 is generated by a cytosolic oxidoreductase. M4 is equipotent to dasatinib and represents approximately 5% of the AUC. However, it is unlikely to play a major role in the observed pharmacology of dasatinib. M5 and M6 are more than 10 times less active than dasatinib and are considered minor circulating metabolites.
Biological Half-Life
The terminal half-life of dasatinib is 3-5 hours.
Toxicity/Toxicokinetics
Hepatotoxicity
In large clinical trials, elevations in serum aminotransferase levels during dasatinib therapy occurred in up to 50% of patients, but were usually mild and self-limited. Elevations above 5 times the upper limit of normal (ULN) occurred in 1% to 9% of patients and generally responded to dose adjustment or temporary discontinuation and restarting at a lower dose, which is recommended if liver test results are markedly elevated (ALT or AST persistently greater than 5 times ULN or bilirubin more than 3 times ULN). While episodes of marked serum aminotransferase elevations with symptoms have been reported, there have been no published reports of clinically apparent liver injury with jaundice attributed to dasatinib therapy. Certainly other tyrosine kinase receptor inhibitors used in the therapy of CML such as imatinib, nilotinib and ponatinib have been associated with cases of acute liver injury with jaundice. With these agents, the liver injury typically arises after several months of therapy and the pattern of serum enzyme elevations is typically hepatocellular. Immunoallergic features (rash, fever and eosinophilia) and autoantibody formation are usually not present.
Reactivation of hepatitis B has been reported with dasatinib as well as imatinib and nilotinib therapy. Reactivation typically occurs in an HBsAg positive person treated with the tyrosine kinase inhibitor for 3 to 6 months, presenting with jaundice, marked serum aminotransferase elevations and an increase in HBV DNA levels. Reactivation of hepatitis B can be severe and fatal instances have been reported after imatinib and nilotinib therapy. Screening of patients for HBsAg and anti-HBc is sometimes recommended before starting cancer chemotherapy and those with HBsAg offered prophylaxis with oral antiviral agents, such as lamivudine, tenofovir or entecavir.
Likelihood score: D (possible cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Although one breastfed infant apparently experienced no adverse effects during maternal use of dasatinib, no long-term data are available. Because dasatinib and its metabolite are more than 90% bound to plasma proteins, the amounts in milk are likely to be low. However, there is little published experience with dasatinib during breastfeeding, and an alternate drug may be preferred, especially while nursing a newborn or preterm infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during dasatinib therapy and the manufacturer recommends withholding breastfeeding until 2 weeks following the last dose.
◉ Effects in Breastfed Infants
A woman with chronic myeloid leukemia received dasatinib 100 mg daily throughout pregnancy and continuing postpartum, apparently while breastfeeding her infant (extent not stated). No adverse reactions were reported in her infant.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
_In vitro_, the binding of dasatinib to human plasma proteins is approximately 96%.
References
[1]. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658-61.
[1]. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500-5.
[2]. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91.
Additional Infomation
Pharmacodynamics
Dasatinib is an orally available small-molecule multikinase inhibitor. During clinical trials, less than 1% of patients treated with dasatinib had QTc prolongation as an adverse reaction, and 1% experienced a QTcF higher than 500 ms. The use of dasatinib is also associated with myelosuppression, bleeding-related events, fluid retention, cardiovascular toxicity, pulmonary arterial hypertension, severe dermatologic reactions, tumor lysis syndrome and hepatotoxicity. It may also cause embryo-fetal toxicity and lead to adverse reactions associated with bone growth and development in pediatric patients.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C22H26CLN7O2S
Molecular Weight
488.01
Exact Mass
487.155
Elemental Analysis
C, 54.15; H, 5.37; Cl, 7.26; N, 20.09; O, 6.56; S, 6.57
CAS #
302962-49-8
Related CAS #
Dasatinib hydrochloride;854001-07-3;Dasatinib monohydrate;863127-77-9;Dasatinib-d8;1132093-70-9; 302962-49-8 (free); 2112837-79-1 (cabaldehyde); 910297-52-8 (N-oxide)
PubChem CID
3062316
Appearance
Typically exists as White to off-white solid at room temperature
Density
1.4±0.1 g/cm3
Melting Point
275-286°C
Index of Refraction
1.688
LogP
2.24
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
9
Rotatable Bond Count
7
Heavy Atom Count
33
Complexity
642
Defined Atom Stereocenter Count
0
SMILES
O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C
InChi Key
XHXFZZNHDVTMLI-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H26ClN7O2S.H2O/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31;/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);1H2
Chemical Name
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide monohydrate.
Synonyms
Trade name: Sprycel; BMS-354825; BMS354825; Sprycel; BMS-354825; Dasatinib anhydrous; BMS 354825; Dasatinib (anhydrous); BMS354825. Dasatinib;
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 98 mg/mL (200.8 mM)
Water:<1 mg/mL
Ethanol:<1 mg/mL
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.


Solubility in Formulation 4: ≥ 2.08 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 5: ≥ 2.08 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

Solubility in Formulation 6: 4% DMSO+30% PEG 300+5% Tween 80+ddH2O:5 mg/mL

Solubility in Formulation 7: 6.67 mg/mL (13.67 mM) in 0.5% MC 0.5% Tween-80 (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.0491 mL 10.2457 mL 20.4914 mL
5 mM 0.4098 mL 2.0491 mL 4.0983 mL
10 mM 0.2049 mL 1.0246 mL 2.0491 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
CTID: NCT01445509
Phase: Phase 1    Status: Completed
Date: 2024-12-02
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
CTID: NCT05192889
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-11-26
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia
CTID: NCT04147533
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-26
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
CTID: NCT03117751
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-11-26
Asciminib Roll-over Study
CTID: NCT04877522
Phase: Phase 4    Status: Recruiting
Date: 2024-11-25
View More

ALSENLITE: Senolytics for Alzheimer's Disease
CTID: NCT04785300
Phase: Phase 1/Phase 2    Status: Enrolling by invitation
Date: 2024-11-25


Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
CTID: NCT04530565
Phase: Phase 3    Status: Recruiting
Date: 2024-11-25
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
CTID: NCT04747912
Phase: Phase 2    Status: Recruiting
Date: 2024-11-22
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
CTID: NCT02465060
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-18
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
CTID: NCT00792948
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
CTID: NCT02883049
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
CTID: NCT00070499
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
CTID: NCT03297606
Phase: Phase 2    Status: Recruiting
Date: 2024-11-12
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
CTID: NCT06533748
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-08
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
CTID: NCT06390319
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-08
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
CTID: NCT02143414
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-23
A Study to Investigate the Safety and Efficacy of KQB198 As Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies
CTID: NCT06645886
Phase: Phase 1    Status: Recruiting
Date: 2024-10-17
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)
CTID: NCT06124157
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-10-10
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
CTID: NCT06055621
Phase: Phase 2    Status: Recruiting
Date: 2024-10-08
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
CTID: NCT01990196
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-01
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
CTID: NCT05724329
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-09-19
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
CTID: NCT02420717
Phase: Phase 2    Status: Terminated
Date: 2024-09-19
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
CTID: NCT02689440
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-09-19
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
CTID: NCT01660971
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-09-19
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
CTID: NCT04872790
Phase: Phase 1    Status: Recruiting
Date: 2024-09-04
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
CTID: NCT05198843
Phase: Phase 1/Phase 2    Status: Terminated
Date: 2024-09-04
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
CTID: NCT02389309
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-08-28
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
CTID: NCT05007873
Phase: Phase 2    Status: Recruiting
Date: 2024-08-27
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
CTID: NCT01751425
Phase: Phase 1    Status: Terminated
Date: 2024-08-26
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
CTID: NCT02559778
Phase: Phase 2    Status: Recruiting
Date: 2024-08-23
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
CTID: NCT03020030
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-08-15
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
CTID: NCT02326311
Phase: Phase 3    Status: Completed
Date: 2024-08-13
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
CTID: NCT03516279
Phase: Phase 2    Status: Recruiting
Date: 2024-08-09
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
CTID: NCT02494882
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-07-29
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
CTID: NCT04329325
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-07-24
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans
CTID: NCT04313634
Phase: Phase 2    Status: Completed
Date: 2024-07-22
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
CTID: NCT01471106
Phase: Phase 2    Status: Completed
Date: 2024-07-10
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
CTID: NCT03654768
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-07-08
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
CTID: NCT06355037
Phase: Phase 2    Status: Recruiting
Date: 2024-07-08
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
CTID: NCT02954523
Phase: Phase 1/Phase 2    Status: Terminated
Date: 2024-07-05
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
CTID: NCT05751044
Phase: Phase 1/Phase 2    Status: Not yet recruiting
Date: 2024-06-21
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
CTID: NCT00254423
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-06-12
Pilot Trial for Treatment of Recurrent Glioblastoma
CTID: NCT05432518
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-06-03
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
CTID: NCT04580121
Phase: Phase 1    Status: Completed
Date: 2024-06-03
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
CTID: NCT04971226
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-05-03
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
CTID: NCT04838041
Phase: Phase 2    Status: Recruiting
Date: 2024-04-03
Ma-Spore ALL 2020 Study
CTID: NCT06336395
Phase: Phase 2    Status: Recruiting
Date: 2024-03-28
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
CTID: NCT05143840
Phase: Phase 2    Status: Recruiting
Date: 2024-03-26
Dasatinib In Waldenström Macroglobulinemia
CTID: NCT04115059
Phase: Phase 1    Status: Terminated
Date: 2024-03-21
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
CTID: NCT02081378
Phase: Phase 1    Status: Completed
Date: 2024-03-18
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
CTID: NCT05422885
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-03-07
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
CTID: NCT05527418
Phase: Phase 2    Status: Recruiting
Date: 2024-03-06
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
CTID: NCT03878524
Phase: Phase 1    Status: Terminated
Date: 2024-03-04
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
CTID: NCT02013648
Phase: Phase 3    Status: Completed
Date: 2024-02-23
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
CTID: NCT04845035
Phase: Phase 2    Status: Withdrawn
Date: 2024-02-22
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
CTID: NCT05993949
Phase: Phase 1    Status: Recruiting
Date: 2024-02-08
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
CTID: NCT00390793
Phase: Phase 2    Status: Completed
Date: 2024-02-07
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
CTID: NCT05653258
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2024-01-17
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
CTID: NCT01514864
Phase: Phase 2    Status: Terminated
Date: 2023-12-19
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
CTID: NCT00364286
Phase: Phase 2    Status: Completed
Date: 2023-12-19
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
CTID: NCT00255346
Phase: Phase 2    Status: Completed
Date: 2023-12-18
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
CTID: NCT01254864
Phase: Phase 2    Status: Completed
Date: 2023-12-15
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment
CTID: NCT05780073
Phase: Phase 2    Status: Recruiting
Date: 2023-12-15
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
CTID: NCT04685590
Phase: Phase 2    Status: Recruiting
Date: 2023-12-14
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
CTID: NCT04164069
Phase: Phase 1    Status: Active, not recruiting
Date: 2023-12-12
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
CTID: NCT03595917
Phase: Phase 1    Status: Recruiting
Date: 2023-12-05
KISS Study: Kinase Inhibition With Sprycel Start up
CTID: NCT03193281
Phase: Phase 2    Status: Active, not recruiting
Date: 2023-11-29
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
CTID: NCT05286528
Phase:    Status: Completed
Date: 2023-10-27
Senolytics to Improve Osteoporosi
Exploring the gastrointestinal behavior of dasatinib in healthy volunteers
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2020-01-24
Frontline Asciminib combination in chronic phase CML
CTID: null
Phase: Phase 2    Status: Trial now transitioned
Date: 2019-11-14
TASTER- TArgeting STEm cell Resistance
CTID: null
Phase: Phase 2    Status: GB - no longer in EU/EEA
Date: 2019-05-28
Gastrointestinal behavior of dasatinib in healthy volunteers
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2019-04-23
PERSISTENCE OF MAJOR MOLECULAR REMISSION IN CHRONIC MYELOID LEUKEMIA AFTER a second stop of TKI TREATMENT in patients who failed an initial stop attempt: A prospective multicenter study .
CTID: null
Phase: Phase 2    Status: Trial now transitioned, Ongoing
Date: 2017-03-06
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer
CTID: null
Phase: Phase 2    Status: Prematurely Ended, Completed
Date: 2017-02-01
D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients with Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab
CTID: null
Phase: Phase 2    Status: Completed
Date: 2016-11-05
Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-08-11
Prospective pilot trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high-grade pineoblastoma
CTID: null
Phase: Phase 2    Status: Completed
Date: 2016-04-07
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
CTID: null
Phase: Phase 2    Status: Completed
Date: 2015-11-09
“Arrest Imatinib or Dasatinib in CML patients with Deep Molecular Responses” (AID MORE)
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2015-09-22
Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma
CTID: null
Phase: Phase 2    Status: Completed
Date: 2015-05-04
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (Biomede)
CTID: null
Phase: Phase 2    Status: Ongoing, Temporarily Halted, Trial now transitioned, GB - no longer in EU/EEA, Completed
Date: 2014-08-25
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-07-14
OPEN LABEL, PHASE IIA MULTICENTER STUDY OF DASATINIB IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL) RELAPSED/REFRACTORY OR NOT AMENABLE TO CONVENTIONAL THERAPY-PTCL-DASA01
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2014-06-10
Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
CTID: null
Phase: Phase 2    Status: Ongoing, Completed
Date: 2013-09-18
A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy DESTINY(De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2013-05-20
A PHASE IV, OPEN-LABEL, MULTICENTER STUDY OF DASATINIB IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS WITH CHRONIC LOW-GRADE NONHEMATOLOGIC TOXICITY TO IMATINIB
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-02-19
An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy with 400 mg Imatinib
CTID: null
Phase: Phase 2    Status: Completed
Date: 2013-01-03
A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ΑLPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
CTID: null
Phase: Phase 2    Status: Ongoing, Completed
Date: 2012-11-01
Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-08-06
Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutation
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-05-09
MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI
CTID: null
Phase: Phase 4    Status: Ongoing, Prematurely Ended, Completed
Date: 2012-04-11
A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
CTID: null
Phase: Phase 2    Status: GB - no longer in EU/EEA, Completed
Date: 2012-02-07
Phase 2 Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-advanced Pancreatic Cancer
CTID: null
Phase: Phase 2    Status: Completed
Date: 2011-10-27
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib plus Smoothen Antagonist (BMS-833923) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
CTID: null
Phase: Phase 2    Status: Completed
Date: 2011-08-26
OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL)
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2011-02-23
Targeted therapy selection based on tumor tissue kinase activity profiles for patients with advanced solid malignancies, an exploratory study
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2010-07-15
Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis (SM)
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2010-01-22
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation
CTID: null
Phase: Phase 2    Status: Prematurely Ended, Completed
Date: 2009-10-08
Randomized phase II of CCNU versus CCNU-dasatinib in patients with recurrent
CTID: null
Phase: Phase 2    Status: Prematurely Ended, Completed
Date: 2009-08-26
Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML)
CTID: null
Phase: Phase 1, Phase 2    Status: Completed
Date: 2009-06-24
An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells with Dasatinib vs. Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
CTID: null
Phase: Phase 2    Status: Ongoing, Completed
Date: 2009-03-23
A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-03-03
A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Exemestane (Aromasin®)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-02-16
A Phase II Study of Dasatinib Therapy in Children and Adolescents with Ph+ Leukemia with Resistance or Intolerance to Imatinib.
CTID: null
Phase: Phase 2    Status: Trial now transitioned, Ongoing, GB - no longer in EU/EEA, Completed
Date: 2009-02-16
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-11-25
A MULTICENTER, OPEN-LABEL, PHASE II STUDY OF DASATINIB IN COMBINATION WITH MELPHALAN AND PREDNISONE (D-MP) IN ADVANCED, RELAPSED / REFRACTORY MULTIPLE MYELOMA PATIENTS.
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2008-10-22
A phase II study in patients with fludarabine refractory CLL: Dasatinib treatment combination for Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2008-07-16
Trial SAKK 56/07 Dasatinib first-line treatment in gastrointestinal stromal tumors. A multicenter phase II trial.
CTID: null
Phase: Phase 2    Status: Ongoing, Completed
Date: 2008-04-29
STI571 Prospective International RandomIsed Trial 2 - A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-04-22
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-11-16
A Phase I Dose Escalation of MK-0457 in Combination With Dasatinib in Patients With Refractory Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
CTID: null
Phase: Phase 1, Phase 2    Status: Prematurely Ended
Date: 2007-09-03
An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2007-08-01
AN OPEN LABEL PHASE II STUDY
CTID: null
Phase: Phase 2    Status: Ongoing, Completed
Date: 2007-06-29
Étude de phase II, multicentrique, en ouvert, évaluant le dasatinib chez les patients atteints de leucémie aiguë myéloblastique (LAM) à core binding factors (CBF) résistants à la chimiothérapie conventionnelle ou en rechute moléculaire.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2007-05-02
Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer
CTID: null
Phase: Phase 2    Status: Completed
Date: 2006-12-21
Phase II Study of Dasatinib (BMS-354825) for Advanced ‘Triple-negative’ Breast Cancer
CTID: null
Phase: Phase 2    Status: Completed
Date: 2006-12-19
Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/neu-Positive Breast Cancer
CTID: null
Phase: Phase 2    Status: Completed
Date: 2006-12-14
A Phase II Multicenter Study on the Treatment of Adult de novo Philadelphia Chromosome Positive Ph Acute Lymphoblastic Leukemia ALL with the Protein Tyrosine Kinase Inhibitor BMS-354825.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2006-09-29
A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to Imatinib
CTID: null
Phase: Phase 2    Status: Prematurely Ended, Completed
Date: 2006-09-15
DASATINIB compassionate use
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2006-07-27
An open-label, randomized study of dasatinib vs. high-dose (800 mg) imatinib in the treatment of subjects with chronic phase chronic myeloid leukemia who have had a suboptimal response after at least 3 months of therapy with 400 mg imatinib.
CTID: null
Phase: Phase 2    Status: Prematurely Ended, Completed
Date: 2006-07-24
Phase I study of Src/Abl tyrosine kinase inhibitor dasatinib [BMS-354825] in children and adolescents with relapsed or refractory leukemia, Protocol ITCC 005.
CTID: null
Phase: Phase 1    Status: Completed
Date: 2006-03-02
A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to Imatinib Mesylate
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-11-16
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-07-18
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-01-25
A Randomized Multi-center Open Label Study of BMS-354825 vs.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-01-25
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid
CTID: null
Phase: Phase 2    Status: Completed
Date: 2004-12-27
A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic
CTID: null
Phase: Phase 2    Status: Completed
Date: 2004-12-27
A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid
CTID: null
Phase: Phase 2    Status: Completed
Date: 2004-12-27
Stop dasatinib study (STDAST)
CTID: jRCTs071180043
Phase:    Status: Complete
Date: 2019-03-14
KSGCT1601(DASALL II)
CTID: jRCTs031180213
Phase:    Status: Complete
Date: 2019-03-08
Phase 1 study to evaluate the safety of dasatinib in relapsed and refractory angioimmunoblastic T-cell lymphoma
CTID: UMIN000025856
Phase:    Status: Complete: follow-up complete
Date: 2017-01-30
Dis

Biological Data
  • Dasatinib

  • Dasatinib

    Dasatinib inhibits splenomegaly and lymphadenopathy in Tg6/λ-MYC mice.Antiviral Res.2012 Jul;95(1):49-56.
  • Dasatinib

    Dasatinib inhibits colony formation by bone marrow cells from LMP2A transgenic (TgE) mice.Antiviral Res.2012 Jul;95(1):49-56.
Contact Us